论文部分内容阅读
对康赛宁Ⅱ期临床试验与Ⅲ期临床试验的疗效及毒副反应作比较,发现从皮下、瘤内、胸腔注射等途径使用康赛宁,Ⅲ期临床的疗效(缓解率分别7.8％、47.6％及有效率95.8％)比Ⅱ期临床的疗效(缓解率分别1.9％、15.4％及有效率83.0％)要好。康赛宁联合化疗治疗肿瘤,从皮下、瘤内途径治疗Ⅲ期临床(44.9％部分缓解,11.5％完全缓解)比Ⅱ期临床(41.7％部分缓解,5.6％完全缓解)有效。扩大使用范围的Ⅲ期临床,其发热、局部反应及皮疹副反应比Ⅱ期临床减少、减轻。没有观察到其它副反应及器官毒性反应,认为康赛宁是治疗肿瘤的安全、有效药物。
Comparing the curative effect and toxic side effects of Phase II clinical trial with Phase III clinical trial, we found that the effect of Phase II clinical trial using Kansai Ning from subcutaneous, intratumoral and intrathoracic injection (response rate 7.8% 47.6% and effective rate of 95.8%) than the clinical efficacy of Ⅱ (response rates were 1.9%, 15.4% and 83.0% efficiency) is better. Concordant combined with chemotherapy for the treatment of tumors, from the subcutaneous, intratumoral treatment of phase Ⅲ clinical (44.9% partial response, 11.5% complete response) than Ⅱ clinical (41.7% partial response, 5.6% complete response) effective. Expand the scope of the use of the phase Ⅲ clinical, fever, local reactions and rash side effects than the clinical phase Ⅱ reduction, reduce. No other side effects or organ toxicity were observed, suggesting that Secacy is a safe and effective drug for the treatment of cancer.